Refine by
Preclinical Drug Articles & Analysis
31 news found
By leveraging a suite of biomimetic and AI-powered technologies, BBBporter™ enables the efficient transport of therapeutic candidates into the brain, opening new avenues for preclinical drug development in areas such as Alzheimer's disease, Parkinson's disease, stroke, and epilepsy. ...
Yang, L., et al (2024) introduces LungVis 1.0, an AI-driven imaging platform integrating light sheet fluorescence microscopy (LSFM) and deep learning for mapping nanoparticle (NP) deposition across murine lungs. The research highlights the advantages of aerosol-based delivery methods over traditional liquid-based approaches, emphasizing the uniformity of NP deposition in distal alveolar ...
Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by progressive scarring of the lungs, which severely impairs lung function over time. Developing effective treatments for IPF has been a challenge for the medical community, as the mechanisms driving this disease are complex and not fully understood. To accelerate drug discovery, animal models that closely mimic the ...
Ace Therapeutics, a preclinical contract research organization (CRO) actively engaged in mental illness research, has announced the launch of its model development services, which aim to revolutionize psychiatric drug research and development. ...
“As the demand for innovative drugs continues to grow, the need for rigorous preclinical research has become paramount. ...
The estimated cost of a failed trial ranges from $800 million to $1.4 billion. 6.Problem setting priorities Clinical trial development involves discovery and development, preclinical research, drug development, FDA review, etc. When working through each phase, a leader decides which tasks should be taken care of first based on the priority. ...
VeriSIM Life has developed a whole-body biosimulation platform driven by AI and machine learning (ML), that accurately predicts the clinical efficacy of new drugs before human trials. We are delivering strategic insights from our platform to translate, scale, and accelerate drug development to advance human health. ...
In the paper, ‘Predicting Regioselectivity of AO, CYP, FMO and UGT Metabolism Using Quantum Mechanical Simulations and Machine Learning’, the team combined existing experimental results, quantum mechanics and machine learning to build predictive models for drug metabolism. [1] The research will underpin the development of new capabilities for StarDrop™, enabling ...
Canaquest Medical Corp (OTC Pink:CANQF) (the "Company" or "CanaQuest"), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in ...
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine (cannabidiol “CBD” + IP, Omega-3s, ...
Our scientists will help fellows proceed with mitochondria-focused design, validation, and test experiment in support of preclinical stages of pharmaceutical drug development," the marketing manager at Creative Biogene said. ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company will be presenting at the H.C. Wainwright Preclinical Cancer Drug Discovery: Emerging Targets and Modalities virtual conference on June 29, 2022. ...
VeriSIM Life (VeriSIM) www.verisimlife.com, a leading artificial intelligence (AI)-enabled company providing services to de-risk R&D decision making for breakthrough drug development, today announced that it has entered into a collaboration with Mayo Clinic to improve the preclinical translation of promising drug candidates. “We are ...
“The initial results from the GARNER Study provide a comprehensive picture of FGFR alteration frequency and other findings and provides a deeper understanding of drivers of disease progression, as well as potential factors related to treatment response and failure or drug resistance,” said Dr Zuiverloon. “We look forward to presenting the initial findings from ...
In this regard, Creative Biogene strives to explore mitochondrial functions that are yet to be discovered as well as the pathogenesis of mitochondria-associated cancers and possible interventions through in-depth mitochondrial function testing to accelerate the preclinical development of novel drugs and therapy targeted to cancer. ...
This strategy expands on Ncardia’s existing drug discovery solutions business and capitalizes on the company’s deep expertise in iPSC differentiation and expansion to focus dedicated resources and capabilities to address the growing need for iPSC cell therapy solutions, including the development of robust cell-specific manufacturing platforms. ...
Profacgen, a state-of-the-art protein service provider located in the USA, provides comprehensive one-stop services for pre-clinical drug development, aiming to evaluate and improve the efficacy and safety of new drug candidates. ...
Creative Biostructure Drug Discovery, a sub-brand of Creative Biostructure, whose mission is to accelerate the preclinical development of innovative drugs through structural insight, recently established a MagHelix™ CADD Platform, a comprehensive platform for new drug discovery that integrates a variety of computer ...
By applying its rT(I)ME Explorer technology, GeneCentric is expanding drug response biomarkers and identifying new targets to enable more effective and efficient drug development. ...
Louis, Mo. with 58,000 square feet of manufacturing and production support at the 5KL processing scale and continued support at the 2KL processing scale. To accelerate preclinical development for biologic drug developers, Thermo Fisher recently introduced its enhanced Quick to Clinic solution, designed to help biopharma companies reach Phase I/First-In-Human ...